Stenocare A/S
CSE:STENO
Operating Margin
Stenocare A/S
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| DK |
S
|
Stenocare A/S
CSE:STENO
|
23.4m DKK |
-1 424%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
744B USD |
40%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
362.6B USD |
26%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2.2T DKK |
45%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
206.8B CHF |
33%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
186.5B CHF |
33%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
163.6B GBP |
24%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
199.5B USD |
34%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
11%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
135.8B USD |
27%
|
Stenocare A/S
Glance View
Stenocare A/S engages in the cultivation, manufacture, and distribution of medical cannabis products. The Company’s business model has two divisions: Import and wholesale of finished medical cannabis products for Danish patients, as well as Operate own cultivation- and production facility in Denmark to produce finished cannabis products for Danish and European patients. The firm distributes its products through pharmacies and hospitals. Stenocare's head office is located in Randers, Denmark.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Stenocare A/S's most recent financial statements, the company has Operating Margin of -1 424.5%.
You don't have any saved screeners yet